KSHV manipulates enzymes to induce cancer, potential treatment implications

Cleveland Clinic researchers discovered Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates human enzymes to induce cancer. The virus affects 10-20% of global cancers and is prevalent in North America, Northern Europe, and Northern Africa. The study led by Dr. Zhao found that inhibiting the virus's metabolic pathway with existing drugs reduced tumor size and increased cancer survival rates in preclinical models. The findings have implications for treating other virus-induced cancers.